活血化瘀中成药非靶向安全药理筛查发现非草药成分致器官损伤
该研究对58种活血化瘀中成药标准提取物在VEGFR2-luc小鼠体内及心、肾、肝细胞体外进行多毒性参数整合评估,识别出脑络通胶囊为强效器官/细胞损伤诱导剂。成分分析显示该胶囊是所集中唯一含非草药成分者,体内外实验证实脑络通胶囊及其化学补充剂盐酸托哌酮通过降低细胞活力、线粒体质量/活性致器官和细胞损伤,而草药组分无此作用。
要点
- 活血化瘀中成药上市后安全性评价仍必要且紧迫。
- 脑络通胶囊含非草药成分,可致器官/细胞损伤。
- 评估草药安全性需考虑化学-草药相互作用。
核心结论
- 活血化瘀中成药(BASR-pCHM)中非草药成分是潜在器官损伤的重要原因,上市后安全性评价仍必要且紧迫。
研究设计与样本
- 研究对58种活血化瘀中成药标准提取物进行体内VEGFR2-luc小鼠和体外心、肾、肝细胞多毒性参数整合评估。
主要发现
- 脑络通胶囊(NLTC)是所检活血化瘀中成药中唯一含非草药成分者,被识别为强效器官/细胞损伤诱导剂。
- 体内外实验证实脑络通胶囊及其化学补充剂盐酸托哌酮通过降低细胞活力、线粒体质量/活性致器官和细胞损伤。
- 脑络通胶囊的草药组分未引起器官和细胞损伤。
临床怎么用
- 临床应用活血化瘀中成药时应关注非草药成分及化学-草药相互作用对安全性的潜在影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Blood activation and stasis removal from circulation is a central principle for treatment of syndromes related to cerebral and cardiovascular diseases in Chinese herbal medicine. However, blood-activating and stasis-removing patent Chinese herbal medicine (BASR-pCHM) widely used with or without prescription in China and elsewhere are highly variable in composition and manufacture standard, making their safety assessment a challenging task. We proposed that an integrated evaluation of multiple toxicity parameters of BASR-pCHM would provide critical reference and guidelines for their safe clinical application. Examination of standardized extracts from 58 compound BASR-pCHM in vivo in VEGFR2-luc mice and in vitro in cardiac, renal, and hepatic cells identified Naoluotong capsule (NLTC) as a potent organ/cell damage inducer. Composition analysis revealed that NLTC was the one that contained nonherbal ingredients among the BASR-pCHM collection. In vivo and in vitro experiments confirmed that NLTC, as well as its chemical supplement tolperisone hydrochloride, caused organ and cell damage by reducing cell viability, mitochondrial mass/activity, while the NLTC herbal components did not. Taken together, our study showed that safety evaluation of patent herbal medicines already on market is still necessary and urgently needed. In addition, chemical/herbal interactions should be considered as an important contributor of potential toxicity when evaluating the safety of herbal medicine.
引用
- Liu X, Shao R, Yang X, et al. Untargeted Safety Pharmacology Screen of Blood-Activating and Stasis-Removing Patent Chinese Herbal Medicines Identified Nonherbal Ingredients as a Cause of Organ Damage in Experimental Models. Front Pharmacol. 2019. PMID: 31607901. doi:10.3389/fphar.2019.00993
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。